ALIVE Israel Healthtech Fund

What is ALIVE Israel Healthtech Fund?

ALIVE Israel Healthtech Fund is a venture capital firm focused on investing in Series A, Series B, Series C, and Pre-IPO stages within the HealthTech sector. It positions itself as a pioneer mid-to-late stage HealthTech fund that delivers a capital efficient model for investors, aiming to offer high rewards with relatively low risk over a condensed investment journey of 3-5 years.

ALIVE leverages an exclusive ecosystem of strategic partners that includes leading hospital chains, HMOs, and financial institutions, to support and accelerate clinical and commercial expansion of its portfolio companies through opportunities like in-depth clinical workflow understanding, access to Key Opinion Leaders (KOLs), and proven hands-on guidance, advancing clinical and commercial activities on a global scale.

The fund evaluates companies with the potential to significantly improve the quality of life for millions of people globally. ALIVE distinguishes the difference between investing in the expansion and growth of innovative companies versus investing purely in innovation itself, noting the unique challenges and skill sets required for each.

Their investment thesis emphasizes the synergy between their portfolio companies and strategic partners to drive expansion.

ALIVE's current portfolio includes companies like Medisafe, Innovalve, Magenta, Cynerio, Beyeonics Vision, Beyeonics Surgical, Nevia Bio, OncoHost, Navina, Wisdo, Append Medical, and Vessi Medical, each focusing on innovative solutions ranging from medication management, minimally invasive medical devices, advanced imaging technologies, AI and biomarkers for early detection, to solutions for cancer treatment, primary care, mental and physical health, and innovative approaches for urological and cardiovascular conditions.